Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Faster acting antidepressants and biomarkers that predict treatment response are needed to facilitate the development of more effective treatments for patients with major depressive disorders. Here, we evaluate implicitly and explicitly processed emotional faces using neuroimaging to identify potential biomarkers of treatment response to the antimuscarinic, scopolamine. METHODS: Healthy participants (n=15) and unmedicated-depressed major depressive disorder patients (n=16) participated in a double-blind, placebo-controlled crossover infusion study using scopolamine (4 μg/kg). Before and following scopolamine, blood oxygen-level dependent signal was measured using functional MRI during a selective attention task. Two stimuli comprised of superimposed pictures of faces and houses were presented. Participants attended to one stimulus component and performed a matching task. Face emotion was modulated (happy/sad) creating implicit (attend-houses) and explicit (attend-faces) emotion processing conditions. The pretreatment difference in blood oxygen-level dependent response to happy and sad faces under implicit and explicit conditions (emotion processing biases) within a-priori regions of interest was correlated with subsequent treatment response in major depressive disorder. RESULTS: Correlations were observed exclusively during implicit emotion processing in the regions of interest, which included the subgenual anterior cingulate (P<.02) and middle occipital cortices (P<.02). CONCLUSIONS: The magnitude and direction of differential blood oxygen-level- dependent response to implicitly processed emotional faces prior to treatment reflect the potential to respond to scopolamine. These findings replicate earlier results, highlighting the potential for pretreatment neural activity in the middle occipital cortices and subgenual anterior cingulate to inform us about the potential to respond clinically to scopolamine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606 · cited 2×
“…rostral portion of BA 24, the infralimbic cortex (BA 25), and the putative prelimbic cortex (BA 32pl) areas implicated in neuroimaging and neuropathological studies of mood disorders (Drevets et al., 1997; Mayberg et al., 1999; Ongur et al., 2003; Mayberg et al., 2005; Price and Drevets, 2010).”
BackgroundSelf-citationSheline, Y. I., Barch, D. M., Donnelly, J. M., Ollinger, J. M., Snyder, A. Z., & Mintun, M. A. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01263-x · Cited by 1,191 · cited 3×
“, 2010, 2012), where patients demonstrate differential neural responses to sad and happy faces under implicit (Sheline et al., 2001; Victor et al., 2010) and explicit (Surguladze et al.”
BackgroundA cholinergic-adrenergic hypothesis of mania and depression
Janowsky, D., Davis, J., El-Yousef, M. K., & Sekerke, H. J. (1972) · The Lancet · doi:10.1016/s0140-6736(72)93021-8 · Cited by 1,134
Cingulate function in depression: a potential predictor of treatment response
Mayberg, H. S., Brannan, S. K., Mahurin, R. K., Jerabek, P. A., Brickman, J. S., Tekell, J. L., Silva, J. A., McGinnis, S., Glass, T. G., Martin, C. C., et al. (1997) · NeuroReport · doi:10.1097/00001756-199703030-00048 · Cited by 1,029
Frontocingulate Dysfunction in Depression: Toward Biomarkers of Treatment Response
Pizzagalli, D. A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.166 · Cited by 945
Architectonic subdivision of the human orbital and medial prefrontal cortex
Öngür, D., Ferry, A. T., & Price, J. L. (2003) · Journal of Comparative Neurology · doi:10.1002/cne.10609 · Cited by 944 · cited 1×
“…rostral portion of BA 24, the infralimbic cortex (BA 25), and the putative prelimbic cortex (BA 32pl) areas implicated in neuroimaging and neuropathological studies of mood disorders (Drevets et al., 1997; Mayberg et al., 1999; Ongur et al., 2003; Mayberg et al., 2005; Price and Drevets, 2010).”
BackgroundAttentional biases for negative interpersonal stimuli in clinical depression
Gotlib, I. H., Krasnoperova, E., Yue, D. N., & Joormann, J. (2004) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.113.1.121 · Cited by 911 · cited 1×
“, 2005) as well as functional neuroimaging studies (Sheline et al., 2001; Fu et al., 2004; Gotlib et al., 2004; Victor et al., 2010, 2012), where patients demonstrate differential neural responses to sad and happy faces under implicit (Sheline et al.”
BackgroundFu, C. H. Y., Williams, S. C. R., Cleare, A. J., Brammer, M. J., Walsh, N. D., Kim, J., Andrew, C. M., Pich, E. M., Williams, P. M., Reed, L. J., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.9.877 · Cited by 775
Sarter, M., Hasselmo, M. E., Bruno, J. P., & Givens, B. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.08.006 · Cited by 667
Emotional bias and inhibitory control processes in mania and depression
MURPHY, F. C., SAHAKIAN, B. J., RUBINSZTEIN, J. S., MICHAEL, A., ROGERS, R. D., ROBBINS, T. W., & PAYKEL, E. S. (1999) · Psychological Medicine · doi:10.1017/s0033291799001233 · Cited by 659
Surguladze, S., Brammer, M. J., Keedwell, P., Giampietro, V., Young, A. W., Travis, M. J., Williams, S. C. R., & Phillips, M. L. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.028 · Cited by 633 · cited 3×
“, 2013), and visual processing areas (Surguladze et al., 2005; Keedwell et al., 2009, 2010).”
BackgroundAntidepressant effect of optogenetic stimulation of the medial prefrontal cortex
Covington, H. E., Lobo, M. K., Maze, I., Vialou, V., Hyman, J. M., Zaman, S., LaPlant, Q., Mouzon, E., Ghose, S., Tamminga, C. A., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1731-10.2010 · Cited by 621 · cited 1×
“Received: July 15, 2014; Revised: February 17, 2015; Accepted: March 1, 2015”
Attentional bias in anxiety and depression: The role of awareness
Mogg, K., Bradley, B. P., & Williams, R. (1995) · British Journal of Clinical Psychology · doi:10.1111/j.2044-8260.1995.tb01434.x · Cited by 559 · cited 2×
“Received: July 15, 2014; Revised: February 17, 2015; Accepted: March 1, 2015”
BackgroundUse of fMRI to Predict Recovery From Unipolar Depression With Cognitive Behavior Therapy
Siegle, G. J., Carter, C. S., & Thase, M. E. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.735 · Cited by 495
The neural substrates of affective processing in depressed patients treated with venlafaxine
Davidson, R. J., Irwin, W., Anderle, M. J., & Kalin, N. H. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.64 · Cited by 487
Furey, M. L., & Drevets, W. C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1121 · Cited by 417 · cited 23×
“The cholinergic neurotransmitter system is implicated in mood disorders (Janowsky et al., 1972a, 1972b; Sitaram et al., 1982; Dube et al., 1985; Janowsky et al., 1994), and the muscariniccholinergic antagonist scopolamine when administered intravenously produces rapid antidepressant effects (within 3 days) in patients…”
BackgroundMethodResultSelf-citationVictor, T. A., Furey, M. L., Fromm, S. J., Öhman, A., & Drevets, W. C. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.144 · Cited by 400 · cited 2×
“, 2010, 2012), where patients demonstrate differential neural responses to sad and happy faces under implicit (Sheline et al., 2001; Victor et al., 2010) and explicit (Surguladze et al.”
BackgroundSelf-citationPersonalized Medicine for Depression: Can We Match Patients With Treatments?
Simon, G. E., & Perlis, R. H. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09111680 · Cited by 365 · cited 1×
“Currently utilized antidepressant agents produce varied clinical responses in patients with major depressive disorder (MDD), and often multiple trials are necessary before an effective therapy is identified (Insel and Wang, 2009; Simon and Perlis, 2010).”
BackgroundSzegedi, A., Jansen, W. T., van Willigenburg, A. P. P., van der Meulen, E., Stassen, H. H., & Thase, M. E. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03780 · Cited by 341 · cited 1×
“Several metaanalyses have reported that clinical status observed at 2 weeks into conventional antidepressant treatment is predictive of subsequent clinical response (Szegedi et al., 2009; Gorwood et al., 2013), allowing for clinical management decisions to be made earlier in the course of treatment.”
BackgroundImplicit and explicit memory for emotion-congruent information in clinical depression and anxiety
Bradley, B. P., Mogg, K., & Williams, R. (1995) · Behaviour Research and Therapy · doi:10.1016/0005-7967(95)00029-w · Cited by 291 · cited 2×
“Received: July 15, 2014; Revised: February 17, 2015; Accepted: March 1, 2015”
BackgroundSalvadore, G., Cornwell, B. R., Colon-Rosario, V., Coppola, R., Grillon, C., Zarate, C. A., & Manji, H. K. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.014 · Cited by 277 · cited 1×
“…2012), cognitive behavior therapy (Siegle et al., 2006), and transcranial magnetic stimulation (Gershon et al., 2003) as well as more experimental approaches that produce a rapid-onset of antidepressant action, including ketamine (Salvadore et al., 2009, 2010) and scopolamine (Furey et al., 2012).”
BackgroundSelf-citationDrevets, W. C., & Furey, M. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.021 · Cited by 241 · cited 24×
“The cholinergic neurotransmitter system is implicated in mood disorders (Janowsky et al., 1972a, 1972b; Sitaram et al., 1982; Dube et al., 1985; Janowsky et al., 1994), and the muscariniccholinergic antagonist scopolamine when administered intravenously produces rapid antidepressant effects (within 3 days) in patients…”
BackgroundMethodResultSelf-citationSerotonin and emotional processing: does it help explain antidepressant drug action?
Harmer, C. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.036 · Cited by 219 · cited 4×
“…and functional neuroimaging measures have been evaluated as markers of antidepressant response to conventional treatments such as SSRI’s (Harmer, 2008; Korb et al., 2009; MacQueen, 2009; Lee et al., 2011; Pizzagalli, 2011; Furey et al., 2012), cognitive behavior therapy (Siegle et al.,…”
BackgroundInfluentialErickson, K., Drevets, W. C., Clark, L., Cannon, D. M., Bain, E. E., Zarate, C. A., Charney, D. S., & Sahakian, B. J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.2171 · Cited by 203 · cited 2×
“…feature of mood disorders is a negative emotion-processing bias where patients demonstrate a bias towards processing negative emotional stimuli over positive stimuli (Bradley et al., 1995, 1996; Mogg et al., 1995; Murphy et al., 1999; Erickson et al., 2005; Harmer, 2008; Koster et al., 2010).”
BackgroundSelf-citationAntidepressant Effects of the Muscarinic Cholinergic Receptor Antagonist Scopolamine: A Review
Drevets, W. C., Zarate, C. A., & Furey, M. L. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.031 · Cited by 195
Self-citationKeedwell, P., Drapier, D., Surguladze, S., Giampietro, V, Brammer, M., & Phillips, M. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108093589 · Cited by 149
Koster, E. H. W., De Raedt, R., Leyman, L., & De Lissnyder, E. (2010) · Behaviour Research and Therapy · doi:10.1016/j.brat.2009.11.004 · Cited by 148
Neuronal coding of implicit emotion categories in the subcallosal cortex in patients with depression
Laxton, A. W., Neimat, J. S., Davis, K. D., Womelsdorf, T., Hutchison, W. D., Dostrovsky, J. O., Hamani, C., Mayberg, H. S., & Lozano, A. M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.029 · Cited by 62
Cited by
Wise, T., Radua, J., Via, E., Cardoner, N., Abe, O., Adams, T. M., Amico, F., Cheng, Y., Cole, J. H., de Azevedo Marques Périco, C., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.72 · Cited by 606
Self-citationNeuroimaging biomarkers as predictors of treatment outcome in Major Depressive Disorder
Fonseka, T. M., MacQueen, G. M., & Kennedy, S. H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.10.049 · Cited by 185
Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics
Dulawa, S. C., & Janowsky, D. S. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0219-x · Cited by 187
Katzman, M., & Sternat, T. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s111818 · Cited by 83
“72 Furthermore, opioid dependence is associated with a reduced hedonic response to positive stimuli and reduced neural activation in the rostral PFC and ventrolateral prefrontal cortex (VLPFC), 73 and buprenorphine and samidorphan exert their antidepressant effects by affecting the levels of…”
Ketamine normalizes brain activity during emotionally valenced attentional processing in depression
Reed, J. L., Nugent, A. C., Furey, M. L., Szczepanik, J. E., Evans, J. W., & Zarate, C. A. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.07.006 · Cited by 67
“occipital gyrus, which is particularly intriguing in light of studies showing that middle occipital activity predicts antidepressant response to scopolamine, a muscarinic antagonist that also modulates glutamate [32, 33].”
Self-citation
Metadata
- Authors
- Furey, M. L., Drevets, W. C., Szczepanik, J., Khanna, A., Nugent, A., & Zarate, C. A.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-03-28
- Volume
- 18
- Issue
- 8
- Pages
- pyv028-pyv028
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2116855542
- Cited by
- 21
- References
- 28
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.